Korean J Gastroenterol.  2023 Aug;82(2):56-62. 10.4166/kjg.2023.089.

Gut Microbiome and Colorectal Cancer

• Gweon TG

• KMID: 2545329
• DOI: http://doi.org/10.4166/kjg.2023.089

Abstract

Colorectal cancer (CRC) is one of the most common cancers in Korea. A majority of CRCs are caused by progressive genomic alterations referred to as the adenoma-carcinoma sequence. The factors that may increase the risk of CRC include obesity and consumption of a high-fat diet, red meat, processed meat, and alcohol. Recently, the role of gut microbiota in the formation, progression and treatment of CRCs has been investigated in depth. An altered gut microbiota can drive carcinogenesis and cause the development of CRC. Studies have also shown the role of gut microbiota in the prevention of CRC and the impact of therapies involving gut microbiota on CRC. Herein, we summarize the current understanding of the role of the gut microbiota in the development of CRC and its therapeutic potential, including the prevention of CRC and in enhancing efficacy of chemotherapy and immunotherapy.

Keyword

Colorectal cancer; Microbiota; Probiotics; Fusobacterium nucleatum

Reference

1. Rubio CA. 2021; Two intertwined compartments coexisting in sporadic conventional colon adenomas. Intest Res. 19:12–20. DOI: 10.5217/ir.2019.00133. PMID: 32079382. PMCID: PMC7873396.

2. Nguyen LH, Goel A, Chung DC. 2020; Pathways of colorectal carcinogenesis. Gastroenterology. 158:291–302. DOI: 10.1053/j.gastro.2019.08.059. PMID: 31622622. PMCID: PMC6981255.

3. Song M, Chan AT, Sun J. 2020; Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology. 158:322–340. DOI: 10.1053/j.gastro.2019.06.048. PMID: 31586566. PMCID: PMC6957737.

4. Scott AJ, Alexander JL, Merrifield CA, et al. 2019; International cancer microbiome consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 68:1624–1632. DOI: 10.1136/gutjnl-2019-318556. PMID: 31092590. PMCID: PMC6709773.

5. Castellarin M, Warren RL, Freeman JD, et al. 2012; Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22:299–306. DOI: 10.1101/gr.126516.111. PMID: 22009989. PMCID: PMC3266037.

6. Feng Q, Liang S, Jia H, et al. 2015; Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 6:6528. DOI: 10.1038/ncomms7528. PMID: 25758642.

7. Yu J, Feng Q, Wong SH, et al. 2017; Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 66:70–78. DOI: 10.1136/gutjnl-2015-309800. PMID: 26408641.

8. Schmitt M, Greten FR. 2021; The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 21:653–667. DOI: 10.1038/s41577-021-00534-x. PMID: 33911231.

9. Beaugerie L, Itzkowitz SH. 2015; Cancers complicating inflammatory bowel disease. N Engl J Med. 372:1441–1452. DOI: 10.1056/NEJMra1403718. PMID: 25853748.

10. Wong SH, Zhao L, Zhang X, et al. 2017; Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 153:1621–1633.e6. DOI: 10.1053/j.gastro.2017.08.022. PMID: 28823860.

11. Lee CH, Koh SJ, Radi ZA, Habtezion A. 2023; Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer. Intest Res. 21:295–305. DOI: 10.5217/ir.2023.00029. PMID: 37248173. PMCID: PMC10397556.

12. Gholizadeh P, Eslami H, Kafil HS. 2017; Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomed Pharmacother. 89:918–925. DOI: 10.1016/j.biopha.2017.02.102. PMID: 28292019.

13. Fung TC, Artis D, Sonnenberg GF. 2014; Anatomical localization of commensal bacteria in immune cell homeostasis and disease. Immunol Rev. 260:35–49. DOI: 10.1111/imr.12186. PMID: 24942680. PMCID: PMC4216679.

14. Ou S, Wang H, Tao Y, et al. 2022; Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism. Front Cell Infect Microbiol. 12:1020583. DOI: 10.3389/fcimb.2022.1020583. PMID: 36523635. PMCID: PMC9745098.

15. Mima K, Cao Y, Chan AT, et al. 2016; Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol. 7:e200. DOI: 10.1038/ctg.2016.53. PMID: 27811909. PMCID: PMC5543402.

16. Yang Y, Weng W, Peng J, et al. 2017; Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 152:851–866.e24. DOI: 10.1053/j.gastro.2016.11.018. PMID: 27876571. PMCID: PMC5555435.

17. Kostic AD, Chun E, Robertson L, et al. 2013; Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 14:207–215. DOI: 10.1016/j.chom.2013.07.007. PMID: 23954159. PMCID: PMC3772512.

18. Chung L, Orberg ET, Geis AL, et al. 2018; Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 23:421. DOI: 10.1016/j.chom.2018.02.004. PMID: 29544099. PMCID: PMC6469393.

19. Périchon B, Lichtl-Häfele J, Bergsten E, et al. 2022; Detection of streptococcus gallolyticus and four other crc-associated bacteria in patient stools reveals a potential "driver" role for enterotoxigenic bacteroides fragilis. Front Cell Infect Microbiol. 12:794391. DOI: 10.3389/fcimb.2022.794391. PMID: 35360109. PMCID: PMC8963412.

20. Wu S, Rhee KJ, Albesiano E, et al. 2009; A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 15:1016–1022. DOI: 10.1038/nm.2015. PMID: 19701202. PMCID: PMC3034219.

21. Puppa MJ, White JP, Sato S, Cairns M, Baynes JW, Carson JA. 2011; Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta. 1812:1601–1606. DOI: 10.1016/j.bbadis.2011.08.010. PMID: 21914473. PMCID: PMC3205242.

22. Wilson MR, Jiang Y, Villalta PW, et al. 2019; The human gut bacterial genotoxin colibactin alkylates DNA. Science. 363:eaar7785. DOI: 10.1126/science.aar7785. PMID: 30765538. PMCID: PMC6407708.

23. Dubinsky V, Dotan I, Gophna U. 2020; Carriage of colibactin-producing bacteria and colorectal cancer risk. Trends Microbiol. 28:874–876. DOI: 10.1016/j.tim.2020.05.015. PMID: 32507544.

24. Arthur JC, Perez-Chanona E, Mühlbauer M, et al. 2012; Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 338:120–123. DOI: 10.1126/science.1224820. PMID: 22903521. PMCID: PMC3645302.

25. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. 2020; Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 580:269–273. DOI: 10.1038/s41586-020-2080-8. PMID: 32106218. PMCID: PMC8142898.

26. Arthur JC, Gharaibeh RZ, Mühlbauer M, et al. 2014; Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 5:4724. DOI: 10.1038/ncomms5724. PMID: 25182170. PMCID: PMC4155410.

27. Yang Y, Gharaibeh RZ, Newsome RC, Jobin C. 2020; Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat Cancer. 1:723–734. DOI: 10.1038/s43018-020-0078-7. PMID: 33768208. PMCID: PMC7990316.

28. Wong SH, Kwong TNY, Chow TC, et al. 2017; Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 66:1441–1448. DOI: 10.1136/gutjnl-2016-312766. PMID: 27797940. PMCID: PMC5530471.

29. Flemer B, Warren RD, Barrett MP, et al. 2018; The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 67:1454–1463. DOI: 10.1136/gutjnl-2017-314814. PMID: 28988196. PMCID: PMC6204958.

30. Komiya Y, Shimomura Y, Higurashi T, et al. 2019; Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut. 68:1335–1337. DOI: 10.1136/gutjnl-2018-316661. PMID: 29934439. PMCID: PMC6582823.

31. Yachida S, Mizutani S, Shiroma H, et al. 2019; Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 25:968–976. DOI: 10.1038/s41591-019-0458-7. PMID: 31171880.

32. Bosch S, Acharjee A, Quraishi MN, et al. 2022; Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer. Gut Microbes. 14:2139979. DOI: 10.1080/19490976.2022.2139979. PMID: 36369736. PMCID: PMC9662191.

33. Dougherty MW, Jobin C. 2023; Intestinal bacteria and colorectal cancer: etiology and treatment. Gut Microbes. 15:2185028. DOI: 10.1080/19490976.2023.2185028. PMID: 36927206. PMCID: PMC10026918.

34. Yu T, Guo F, Yu Y, et al. 2017; Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 170:548–563.e16. DOI: 10.1016/j.cell.2017.07.008. PMID: 28753429. PMCID: PMC5767127.

35. Zorron Cheng Tao Pu L, Yamamoto K, Honda T, et al. 2020; Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon. J Gastroenterol Hepatol. 35:433–437. DOI: 10.1111/jgh.14868. PMID: 31609493.

36. Mima K, Nishihara R, Qian ZR, et al. 2016; Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 65:1973–1980. DOI: 10.1136/gutjnl-2015-310101. PMID: 26311717. PMCID: PMC4769120.

37. Iida N, Dzutsev A, Stewart CA, et al. 2013; Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 342:967–970. DOI: 10.1126/science.1240527. PMID: 24264989. PMCID: PMC6709532.

38. Machover D, Diaz-Rubio E, de Gramont A, et al. 1996; Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 7:95–98. DOI: 10.1093/oxfordjournals.annonc.a010489. PMID: 9081400.

39. Wiseman LR, Adkins JC, Plosker GL, Goa KL. 1999; Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Aging. 14:459–475. DOI: 10.2165/00002512-199914060-00006. PMID: 10408744.

40. Hou XY, Zhang P, Du HZ, et al. 2021; Prevotella contributes to individual response of FOLFOX in colon cancer. Clin Transl Med. 11:e512. DOI: 10.1002/ctm2.512.

41. Baldwin C, Millette M, Oth D, Ruiz MT, Luquet FM, Lacroix M. 2010; Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer. 62:371–378. DOI: 10.1080/01635580903407197. PMID: 20358475.

42. Bullman S, Pedamallu CS, Sicinska E, et al. 2017; Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 358:1443–1448. DOI: 10.1126/science.aal5240. PMID: 29170280. PMCID: PMC5823247.

43. Dong X, Pan P, Zheng DW, Bao P, Zeng X, Zhang XZ. 2020; Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. Sci Adv. 6:eaba1590. DOI: 10.1126/sciadv.aba1590. PMID: 32440552. PMCID: PMC7228756.

44. Baruch EN, Youngster I, Ben-Betzalel G, et al. 2021; Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 371:602–609. DOI: 10.1126/science.abb5920. PMID: 33303685.

45. Sehgal K, Khanna S. 2021; Gut microbiome and checkpoint inhibitor colitis. Intest Res. 19:360–364. DOI: 10.5217/ir.2020.00116. PMID: 33249800. PMCID: PMC8566823.

46. Wang Y, Wiesnoski DH, Helmink BA, et al. 2018; Fecal microbiota transplantation for refractory immune checkpoint inhibitorassociated colitis. Nat Med. 24:1804–1808. DOI: 10.1038/s41591-018-0238-9. PMID: 30420754. PMCID: PMC6322556.

47. Katona BW, Weiss JM. 2020; Chemoprevention of colorectal cancer. Gastroenterology. 158:368–388. DOI: 10.1053/j.gastro.2019.06.047. PMID: 31563626. PMCID: PMC6981249.

48. Zhao R, Coker OO, Wu J, et al. 2020; Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects. Gastroenterology. 159:969–983.e4. DOI: 10.1053/j.gastro.2020.05.004. PMID: 32387495.

49. Wong CC, Yu J. 2023; Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol. 20:429–452. DOI: 10.1038/s41571-023-00766-x. PMID: 37169888.

50. Kvakova M, Kamlarova A, Stofilova J, Benetinova V, Bertkova I. 2022; Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy. World J Gastroenterol. 28:3370–3382. DOI: 10.3748/wjg.v28.i27.3370. PMID: 36158273. PMCID: PMC9346452.

51. Dai Z, Coker OO, Nakatsu G, et al. 2018; Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 6:70. DOI: 10.1186/s40168-018-0451-2. PMID: 29642940. PMCID: PMC5896039.

52. Del Carmen S, de Moreno de LeBlanc A, Levit R, et al. 2017; Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. Int Immunopharmacol. 42:122–129. DOI: 10.1016/j.intimp.2016.11.017. PMID: 27912148.

53. Sugimura N, Li Q, Chu ESH, et al. 2021; Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut. 71:2011–2021. DOI: 10.1136/gutjnl-2020-323951. PMID: 34937766. PMCID: PMC9484392.

54. Li Q, Hu W, Liu WX, et al. 2021; Streptococcus thermophilus inhibits colorectal tumorigenesis through secreting β-galactosidase. Gastroenterology. 160:1179–1193.e14. DOI: 10.1053/j.gastro.2020.09.003. PMID: 32920015.

55. Osterlund P, Ruotsalainen T, Korpela R, et al. 2007; Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 97:1028–1034. DOI: 10.1038/sj.bjc.6603990. PMID: 17895895. PMCID: PMC2360429.

56. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. 2015; Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 26:26191. DOI: 10.3402/mehd.v26.26191. PMID: 25651997. PMCID: PMC4315779.

57. Kim SH, Lim YJ. 2022; The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment. Intest Res. 20:31–42. DOI: 10.5217/ir.2021.00034. PMID: 34015206. PMCID: PMC8831768.